Search research articles
Contact Us
Filters
Showing results (671-680 of 759) with videos related to
Page
of 76
Sort By:
Leukemia
|
March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria
Eli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Leukemia
|
May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
Charles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.
Blood Cancer Journal
|
August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
Shaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings
|
December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
Shaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 18, 2013
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma
Ayman Saad, Anuj Mahindra, Mei-Jie Zhang, et al.
Transplantation and Cellular Therapy
|
August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
Mohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Annals of Hematology
|
April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
Jonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood
|
October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Leukemia
|
February 28, 2018
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis
Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Mayo Clinic Proceedings
|
June 26, 2019
Oncolytic Measles Virotherapy and Opposition to Measles Vaccination
Stephen J Russell, Dusica Babovic-Vuksanovic, Alice Bexon, et al.
Page
of 76
Search research articles
Search
Showing results (671-680 of 759) with videos related to
Sort By:
Page
of 76
Leukemia
|
March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria
Eli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Leukemia
|
May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
Charles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.
Blood Cancer Journal
|
August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
Shaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings
|
December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
Shaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 18, 2013
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma
Ayman Saad, Anuj Mahindra, Mei-Jie Zhang, et al.
Transplantation and Cellular Therapy
|
August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
Mohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Annals of Hematology
|
April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
Jonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood
|
October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Leukemia
|
February 28, 2018
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis
Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Mayo Clinic Proceedings
|
June 26, 2019
Oncolytic Measles Virotherapy and Opposition to Measles Vaccination
Stephen J Russell, Dusica Babovic-Vuksanovic, Alice Bexon, et al.
Page
of 76